Other intangible assets

12 Months Ended

Dec. 31, 2024

Intangible assets other than goodwill [abstract]

Other intangible assets

10. Other intangible assets

	Capitalized development expenditures	Patents, concessions and licenses	Other intangible assets	Total
	(€ million)
Gross carrying amount at January 1, 2023	€32,981	€916	€4,299	€38,196
Additions	4,352	98	270	4,720
Divestitures	(49)	(13)	(334)	(396)
Change in scope of consolidation	5	6	29	40
Translation differences and other changes	(503)	—	(26)	(529)
At December 31, 2023	36,786	1,007	4,238	42,031
Additions	4,150	82	454	4,686
Divestitures	(150)	(20)	(707)	(877)
Change in scope of consolidation	230	(2)	35	263
Transfer to Assets held for sale	—	—	(1)	(1)
Translation differences and other changes	677	23	92	792
At December 31, 2024	41,693	1,090	4,111	46,894
Accumulated amortization and impairment losses at January 1, 2023	17,277	551	1,362	19,190
Amortization	2,193	92	200	2,485
Impairment losses and asset write-offs	122	—	—	122
Divestitures	(38)	(11)	(3)	(52)
Change in scope of consolidation	5	5	17	27
Translation differences and other changes	(348)	(3)	(15)	(366)
At December 31, 2023	19,211	634	1,561	21,406
Amortization	2,149	98	211	2,458
Impairment losses, reversals and asset write-offs	693	1	—	694
Divestitures	(156)	(19)	(28)	(203)
Change in scope of consolidation	(30)	—	3	(27)
Translation differences and other changes	159	5	23	187
At December 31, 2024	22,026	719	1,770	24,515
Carrying amount at December 31, 2023	€17,575	€373	€2,677	€20,625
Carrying amount at December 31, 2024	€19,667	€371	€2,341	€22,379

Capitalized development expenditures included both internal and external costs that were directly attributable to the

internal product development process, primarily consisting of material costs and personnel related expenses relating to

engineering, design and development focused on content enhancement of existing vehicles, new models and propulsion

system programs.

In 2024, €694 million of impairment losses and asset write-offs were recognized, refer to Note 2, Basis of

preparation - Critical judgements and use of estimates - Recoverability of non-current assets with definite useful lives for

additional information on the impairment losses and asset write-offs recognized.

In 2023, €122 million of impairment losses and asset write-offs were recognized.

At December 31, 2024 and 2023, translation differences primarily related to depreciation of the Euro compared to

the U.S. Dollar.

Amortization of capitalized development expenditures was recognized within Research and development costs

within the Consolidated Income Statement, as described in Note 5, Research and development costs. Amortization of patents,

concessions, licenses and other intangibles are recognized within Cost of revenues and Selling, general and other costs.

At December 31, 2024 and 2023, the Company had contractual commitments for the purchase of intangible assets

amounting to €331 million and €133 million, respectively.